Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Commentary

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2008, Vol.111 (3)
Hauptverfasser: MESA, Ruben A, HOCHHAUS, Andreas, GOLDMAN, John, FISCHER, Thomas, O'BRIEN, Stephen G, REIFFERS, Jose J, MONE, Manisha, KRAHNKE, Tillmann, TALPAZ, Moshe, KANTARJIAN, Hagop M, DRUKER, Brian, SAWYERS, Charles, GUILHOT, Francois, SCHIFFER, Charles A, CORTES, Jorge, NIEDERWIESER, Dietger W, GAMBACORTI, Carlo, STONE, Richard M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 3
container_start_page
container_title Blood
container_volume 111
creator MESA, Ruben A
HOCHHAUS, Andreas
GOLDMAN, John
FISCHER, Thomas
O'BRIEN, Stephen G
REIFFERS, Jose J
MONE, Manisha
KRAHNKE, Tillmann
TALPAZ, Moshe
KANTARJIAN, Hagop M
DRUKER, Brian
SAWYERS, Charles
GUILHOT, Francois
SCHIFFER, Charles A
CORTES, Jorge
NIEDERWIESER, Dietger W
GAMBACORTI, Carlo
STONE, Richard M
description
format Article
fullrecord <record><control><sourceid>pascalfrancis</sourceid><recordid>TN_cdi_pascalfrancis_primary_20047384</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20047384</sourcerecordid><originalsourceid>FETCH-pascalfrancis_primary_200473843</originalsourceid><addsrcrecordid>eNqNTklOw0AQtBBImOUPfeGWQeMlC-eIiAdwjzpODx6YxeoeO5pn8REufAhHgjun2qW6KMpqWW-U1rW-LEqt9Uq1T-vqurgRede6apt6WRbfO5wi48ERuBjeVCL2YKJz8aTGAZhkdEkgTsSwgkzIMsd8DoYYhBYgI092QrcADEcQNJQynGzqwXpMNtgDeJLsMBGknhiHDDZA13MMtlNDj0J_CnwmF-0RHI0f5C0CmvkRGLRuZIJo5ulsGJrr6usTEhMmTyE9wjb6M0HOd8WVQSd0_4u3xcPu-XX7ogaUDp1hDJ2V_cDzQc77Wut23Wza5r-9H0eXdLo</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Commentary</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>MESA, Ruben A ; HOCHHAUS, Andreas ; GOLDMAN, John ; FISCHER, Thomas ; O'BRIEN, Stephen G ; REIFFERS, Jose J ; MONE, Manisha ; KRAHNKE, Tillmann ; TALPAZ, Moshe ; KANTARJIAN, Hagop M ; DRUKER, Brian ; SAWYERS, Charles ; GUILHOT, Francois ; SCHIFFER, Charles A ; CORTES, Jorge ; NIEDERWIESER, Dietger W ; GAMBACORTI, Carlo ; STONE, Richard M</creator><creatorcontrib>MESA, Ruben A ; HOCHHAUS, Andreas ; GOLDMAN, John ; FISCHER, Thomas ; O'BRIEN, Stephen G ; REIFFERS, Jose J ; MONE, Manisha ; KRAHNKE, Tillmann ; TALPAZ, Moshe ; KANTARJIAN, Hagop M ; DRUKER, Brian ; SAWYERS, Charles ; GUILHOT, Francois ; SCHIFFER, Charles A ; CORTES, Jorge ; NIEDERWIESER, Dietger W ; GAMBACORTI, Carlo ; STONE, Richard M</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><language>eng</language><publisher>Washington, DC: The Americain Society of Hematology</publisher><subject>Biological and medical sciences ; Hematologic and hematopoietic diseases ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences</subject><ispartof>Blood, 2008, Vol.111 (3)</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,4011</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20047384$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>MESA, Ruben A</creatorcontrib><creatorcontrib>HOCHHAUS, Andreas</creatorcontrib><creatorcontrib>GOLDMAN, John</creatorcontrib><creatorcontrib>FISCHER, Thomas</creatorcontrib><creatorcontrib>O'BRIEN, Stephen G</creatorcontrib><creatorcontrib>REIFFERS, Jose J</creatorcontrib><creatorcontrib>MONE, Manisha</creatorcontrib><creatorcontrib>KRAHNKE, Tillmann</creatorcontrib><creatorcontrib>TALPAZ, Moshe</creatorcontrib><creatorcontrib>KANTARJIAN, Hagop M</creatorcontrib><creatorcontrib>DRUKER, Brian</creatorcontrib><creatorcontrib>SAWYERS, Charles</creatorcontrib><creatorcontrib>GUILHOT, Francois</creatorcontrib><creatorcontrib>SCHIFFER, Charles A</creatorcontrib><creatorcontrib>CORTES, Jorge</creatorcontrib><creatorcontrib>NIEDERWIESER, Dietger W</creatorcontrib><creatorcontrib>GAMBACORTI, Carlo</creatorcontrib><creatorcontrib>STONE, Richard M</creatorcontrib><title>Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Commentary</title><title>Blood</title><subject>Biological and medical sciences</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqNTklOw0AQtBBImOUPfeGWQeMlC-eIiAdwjzpODx6YxeoeO5pn8REufAhHgjun2qW6KMpqWW-U1rW-LEqt9Uq1T-vqurgRede6apt6WRbfO5wi48ERuBjeVCL2YKJz8aTGAZhkdEkgTsSwgkzIMsd8DoYYhBYgI092QrcADEcQNJQynGzqwXpMNtgDeJLsMBGknhiHDDZA13MMtlNDj0J_CnwmF-0RHI0f5C0CmvkRGLRuZIJo5ulsGJrr6usTEhMmTyE9wjb6M0HOd8WVQSd0_4u3xcPu-XX7ogaUDp1hDJ2V_cDzQc77Wut23Wza5r-9H0eXdLo</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>MESA, Ruben A</creator><creator>HOCHHAUS, Andreas</creator><creator>GOLDMAN, John</creator><creator>FISCHER, Thomas</creator><creator>O'BRIEN, Stephen G</creator><creator>REIFFERS, Jose J</creator><creator>MONE, Manisha</creator><creator>KRAHNKE, Tillmann</creator><creator>TALPAZ, Moshe</creator><creator>KANTARJIAN, Hagop M</creator><creator>DRUKER, Brian</creator><creator>SAWYERS, Charles</creator><creator>GUILHOT, Francois</creator><creator>SCHIFFER, Charles A</creator><creator>CORTES, Jorge</creator><creator>NIEDERWIESER, Dietger W</creator><creator>GAMBACORTI, Carlo</creator><creator>STONE, Richard M</creator><general>The Americain Society of Hematology</general><scope>IQODW</scope></search><sort><creationdate>2008</creationdate><title>Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Commentary</title><author>MESA, Ruben A ; HOCHHAUS, Andreas ; GOLDMAN, John ; FISCHER, Thomas ; O'BRIEN, Stephen G ; REIFFERS, Jose J ; MONE, Manisha ; KRAHNKE, Tillmann ; TALPAZ, Moshe ; KANTARJIAN, Hagop M ; DRUKER, Brian ; SAWYERS, Charles ; GUILHOT, Francois ; SCHIFFER, Charles A ; CORTES, Jorge ; NIEDERWIESER, Dietger W ; GAMBACORTI, Carlo ; STONE, Richard M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pascalfrancis_primary_200473843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biological and medical sciences</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MESA, Ruben A</creatorcontrib><creatorcontrib>HOCHHAUS, Andreas</creatorcontrib><creatorcontrib>GOLDMAN, John</creatorcontrib><creatorcontrib>FISCHER, Thomas</creatorcontrib><creatorcontrib>O'BRIEN, Stephen G</creatorcontrib><creatorcontrib>REIFFERS, Jose J</creatorcontrib><creatorcontrib>MONE, Manisha</creatorcontrib><creatorcontrib>KRAHNKE, Tillmann</creatorcontrib><creatorcontrib>TALPAZ, Moshe</creatorcontrib><creatorcontrib>KANTARJIAN, Hagop M</creatorcontrib><creatorcontrib>DRUKER, Brian</creatorcontrib><creatorcontrib>SAWYERS, Charles</creatorcontrib><creatorcontrib>GUILHOT, Francois</creatorcontrib><creatorcontrib>SCHIFFER, Charles A</creatorcontrib><creatorcontrib>CORTES, Jorge</creatorcontrib><creatorcontrib>NIEDERWIESER, Dietger W</creatorcontrib><creatorcontrib>GAMBACORTI, Carlo</creatorcontrib><creatorcontrib>STONE, Richard M</creatorcontrib><collection>Pascal-Francis</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MESA, Ruben A</au><au>HOCHHAUS, Andreas</au><au>GOLDMAN, John</au><au>FISCHER, Thomas</au><au>O'BRIEN, Stephen G</au><au>REIFFERS, Jose J</au><au>MONE, Manisha</au><au>KRAHNKE, Tillmann</au><au>TALPAZ, Moshe</au><au>KANTARJIAN, Hagop M</au><au>DRUKER, Brian</au><au>SAWYERS, Charles</au><au>GUILHOT, Francois</au><au>SCHIFFER, Charles A</au><au>CORTES, Jorge</au><au>NIEDERWIESER, Dietger W</au><au>GAMBACORTI, Carlo</au><au>STONE, Richard M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Commentary</atitle><jtitle>Blood</jtitle><date>2008</date><risdate>2008</risdate><volume>111</volume><issue>3</issue><issn>0006-4971</issn><eissn>1528-0020</eissn><cop>Washington, DC</cop><pub>The Americain Society of Hematology</pub></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2008, Vol.111 (3)
issn 0006-4971
1528-0020
language eng
recordid cdi_pascalfrancis_primary_20047384
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Biological and medical sciences
Hematologic and hematopoietic diseases
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
title Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Commentary
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T09%3A59%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pascalfrancis&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Favorable%20long-term%20follow-up%20results%20over%206%20years%20for%20response,%20survival,%20and%20safety%20with%20imatinib%20mesylate%20therapy%20in%20chronic-phase%20chronic%20myeloid%20leukemia%20after%20failure%20of%20interferon-%CE%B1%20treatment.%20Commentary&rft.jtitle=Blood&rft.au=MESA,%20Ruben%20A&rft.date=2008&rft.volume=111&rft.issue=3&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/&rft_dat=%3Cpascalfrancis%3E20047384%3C/pascalfrancis%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true